European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a blank-check company formed to pursue a business combination in the European biotechnology and life sciences sector. The SPAC completed its initial public offering in 2021 and has targeted companies operating across therapeutic development, medical technology, and related healthcare sub-sectors in Europe. As of its 10-Q filed on November 14, 2022, the company remained in its search phase, actively evaluating prospective targets. The filing, bearing accession number 0001193125-22-284207, reflects quarterly reporting obligations during the combination search window. Visit SpacDesk and sign up for full data, filings, and deal-tracking on EBAC and hundreds of other active SPACs.